Biomarkers and GI Cancers

News
Novel Plasma MDMs Accurately Detect Distant Recurrent CRC
06/17/2020
Study findings suggest that MDMs in plasma are a promising method for accurately detecting distant recurrent CRC.
Study findings suggest that MDMs in plasma are a promising method for accurately detecting distant recurrent CRC.
Study findings suggest that MDMs...
06/17/2020
Oncology
Conference Insider
Biomarker Analysis Supports Using Surveillance vs Maintenance Therapy for Advanced OGA
05/28/2020
Interim findings from the PLATFORM study do not support the use of capecitabine or durvalumab maintenance therapy vs surveillance in patients with advanced OGA.
Interim findings from the PLATFORM study do not support the use of capecitabine or durvalumab maintenance therapy vs surveillance in patients with advanced OGA.
Interim findings from the...
05/28/2020
Oncology
Conference Insider
Pembrolizumab Exhibits Antitumor Activity in Advanced ASCC Regardless of PD-L1 Expression
05/28/2020
In a phase 2 study of heavily pretreated patients with advanced ASCC, pembrolizumab was active and yielded manageable toxicity, regardless of PD-L1 status.
In a phase 2 study of heavily pretreated patients with advanced ASCC, pembrolizumab was active and yielded manageable toxicity, regardless of PD-L1 status.
In a phase 2 study of heavily...
05/28/2020
Oncology
Conference Insider
ctDNA a Promising Biomarker for Monitoring Treatment Response, Disease Progression in HCC
05/26/2020
ctDNA is a promising, emerging biomarker to monitor treatment responses and disease progression in patients with HCC.
ctDNA is a promising, emerging biomarker to monitor treatment responses and disease progression in patients with HCC.
ctDNA is a promising, emerging...
05/26/2020
Oncology
Conference Insider
CHIP Crucial for ctDNA Analysis, Frequently Involves Specific Genes
05/26/2020
Researchers posit that CHIP is an important factor in ctDNA analysis, and that the most common genes CHIP involves are DNMT3A, TET2, and TP53.
Researchers posit that CHIP is an important factor in ctDNA analysis, and that the most common genes CHIP involves are DNMT3A, TET2, and TP53.
Researchers posit that CHIP is...
05/26/2020
Oncology
Conference Insider
ctDNA Detects MRD in Real-World Study of Patients With Early, Advanced CRC
05/26/2020
Experts have used ctDNA concentration to detect MRD in patients with early-stage and advanced CRC, according to real-world study data.
Experts have used ctDNA concentration to detect MRD in patients with early-stage and advanced CRC, according to real-world study data.
Experts have used ctDNA...
05/26/2020
Oncology
Conference Insider
Long-Term ctDNA Analyses Test Risk for Recurrence in Patients With CRC
05/26/2020
ctDNA analyses conducted in patients with CRC can detect those with a high risk for recurrence with almost 100% specificity.
ctDNA analyses conducted in patients with CRC can detect those with a high risk for recurrence with almost 100% specificity.
ctDNA analyses conducted in...
05/26/2020
Oncology

Upcoming Events

February 2 ⁠–⁠ February 5
Western AF Symposium
February 27 ⁠–⁠ March 1
DCLF
March 17 ⁠–⁠ March 19
NP Institute
March 27 ⁠–⁠ March 30
TCIV
March 31 ⁠–⁠ April 2
Rx summit logo
April 21 ⁠–⁠ April 24
SAWC Spring
April 30 ⁠–⁠ May 4
Symposium on Advanced Wound Care
April 30 ⁠–⁠ May 5
WoundCon
May 1 ⁠–⁠ May 3
Senior Living Executive Conference
May 19 ⁠–⁠ May 21
See Full Calendar

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use